The safety of the electroconvulsive therapy-aripiprazole combination: Four case reports

Journal of ECT

Volumn 24, Issue 3, 2008, Pages 236-238

  Masdrakis, Vasilios G ^a,b   Oulis, Panagiotis ^a   Zervas, Iannis M ^a   Karakatsanis, Nikolaos A ^a   Kouzoupis, Anastasios V ^a   Karapoulios, Evangelos ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aripiprazole; Electroconvulsive therapy; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; LEVOMEPROMAZINE; LITHIUM SULFATE; PARACETAMOL; QUETIAPINE; VENLAFAXINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DISEASE EXACERBATION; DIZZINESS; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HEADACHE; HUMAN; MAJOR DEPRESSION; MEMORY DISORDER; MYALGIA; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; RELAPSE; RISK ASSESSMENT; SCHIZOPHRENIA; THERAPY RESISTANCE; TREATMENT RESPONSE; HOSPITAL PATIENT; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SAFETY;

ADULT; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; INPATIENTS; MIDDLE AGED; PIPERAZINES; QUINOLONES; SAFETY; SCHIZOPHRENIA;

EID: 58749115394     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e3181571c0e     Document Type: Article

References (23)

1. Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord. 2001;63:1-15.
2. Datto CJ. Side effects of electroconvulsive therapy. Depress Anxiety. 2000;12:130-134.
3. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005;21:75-83.
4. Nothdurfter C, Eser D, Schüle C, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2006;7:162-170.
5. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. J ECT. 2006;22:59-66.
6. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics. Two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci. 2005;255:190-201.
7. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
8. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1213-1219.
9. Dew RE, Rosenquist PB, McCall WV. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health. 2005;17:187-188.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed 4th, text revision. Washington DC: American Psychiatric Association; 2000.
11. Zervas IM, Papakostas YG, Theodoropoulou MA, et al. Thyrotropin-releasing hormone administration does not affect seizure threshold during electroconvulsive therapy. J ECT. 2003;19:136-138.
12. Petrides G, Fink M. The 'half-age' stimulation strategy for ECT dosing. Convuls Ther. 1996;12:138-146.
13. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
14. Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. J ECT. 2002;18:90-94.
15. Gazdag G, Barna I, Ivanyi Z, et al. The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. Ideggyogy Sz. 2004;57:385-390.
16. Tan QR, Wang W, Wang HH, et al. Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report. Clin Neuropharmacol. 2006;29:154-156.
17. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;2:CD004578.
18. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64: 1715-1736.
19. Sachs G, Sanchez R, Markus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546.
20. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment resistant major depressive disorder. J Clin Psychiatry. 2005;66:1326-1330.
21. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216-1220.
22. Bernardo M, Navarro V, Salva J, et al. Seizure activity and safety in combined treatment with venlafaxine and ECT: a pilot study. J ECT. 2000;16:38-42.
23. Baghai TC, Marcuse A, Brosch M, et al. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2006;7:82-90.